Differences in the production of spliced antigenic peptides by the standard proteasome and the immunoproteasome - PubMed (original) (raw)
doi: 10.1002/eji.201040750. Epub 2010 Dec 9.
Affiliations
- PMID: 21182075
- DOI: 10.1002/eji.201040750
Free article
Differences in the production of spliced antigenic peptides by the standard proteasome and the immunoproteasome
Alexandre Dalet et al. Eur J Immunol. 2011 Jan.
Free article
Abstract
Peptide splicing allows the production of antigenic peptides composed of two fragments initially non-contiguous in the parental protein. The proposed mechanism of splicing is a transpeptidation occurring within the proteasome. Three spliced peptides, derived from FGF-5, melanoma protein gp100 and nuclear protein SP110, have been described. Here, we compared the production of these spliced peptides by the standard proteasome and the immunoproteasome. Differential isotope labelling was used to quantify (by mass spectrometry) the fragments contained in digests obtained with precursor peptides and purified proteasomes. The results show that both the standard and the immunoproteasomes can produce spliced peptides although they differ in their efficiency of production of each peptide. The FGF-5 and gp100 peptides are more efficiently produced by the standard proteasome, whereas the SP110 peptide is more efficiently produced by the immunoproteasome. This seems to result from differences in the production of the two splicing partners, which depends on a balance between cleavages liberating or destroying those fragments. By showing that splicing depends on the efficiency of production of the splicing partners, these results also support the transpeptidation model of peptide splicing. Furthermore, given the presence of immunoproteasomes in dendritic cells and cells exposed to IFN-γ, the findings may be relevant for vaccine design.
Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Similar articles
- Splicing of distant peptide fragments occurs in the proteasome by transpeptidation and produces the spliced antigenic peptide derived from fibroblast growth factor-5.
Dalet A, Vigneron N, Stroobant V, Hanada K, Van den Eynde BJ. Dalet A, et al. J Immunol. 2010 Mar 15;184(6):3016-24. doi: 10.4049/jimmunol.0901277. Epub 2010 Feb 12. J Immunol. 2010. PMID: 20154207 - A spliced antigenic peptide comprising a single spliced amino acid is produced in the proteasome by reverse splicing of a longer peptide fragment followed by trimming.
Michaux A, Larrieu P, Stroobant V, Fonteneau JF, Jotereau F, Van den Eynde BJ, Moreau-Aubry A, Vigneron N. Michaux A, et al. J Immunol. 2014 Feb 15;192(4):1962-71. doi: 10.4049/jimmunol.1302032. Epub 2014 Jan 22. J Immunol. 2014. PMID: 24453253 - Analysis of the processing of seven human tumor antigens by intermediate proteasomes.
Guillaume B, Stroobant V, Bousquet-Dubouch MP, Colau D, Chapiro J, Parmentier N, Dalet A, Van den Eynde BJ. Guillaume B, et al. J Immunol. 2012 Oct 1;189(7):3538-47. doi: 10.4049/jimmunol.1103213. Epub 2012 Aug 27. J Immunol. 2012. PMID: 22925930 - Proteasome subtypes and the processing of tumor antigens: increasing antigenic diversity.
Vigneron N, Van den Eynde BJ. Vigneron N, et al. Curr Opin Immunol. 2012 Feb;24(1):84-91. doi: 10.1016/j.coi.2011.12.002. Epub 2011 Dec 27. Curr Opin Immunol. 2012. PMID: 22206698 Review. - Peptide splicing by the proteasome.
Vigneron N, Ferrari V, Stroobant V, Abi Habib J, Van den Eynde BJ. Vigneron N, et al. J Biol Chem. 2017 Dec 22;292(51):21170-21179. doi: 10.1074/jbc.R117.807560. Epub 2017 Nov 6. J Biol Chem. 2017. PMID: 29109146 Free PMC article. Review.
Cited by
- Protein degradation by human 20S proteasomes elucidates the interplay between peptide hydrolysis and splicing.
Soh WT, Roetschke HP, Cormican JA, Teo BF, Chiam NC, Raabe M, Pflanz R, Henneberg F, Becker S, Chari A, Liu H, Urlaub H, Liepe J, Mishto M. Soh WT, et al. Nat Commun. 2024 Feb 7;15(1):1147. doi: 10.1038/s41467-024-45339-3. Nat Commun. 2024. PMID: 38326304 Free PMC article. - Using mass spectrometry to identify neoantigens in autoimmune diseases: The type 1 diabetes example.
Lichti CF, Wan X. Lichti CF, et al. Semin Immunol. 2023 Mar;66:101730. doi: 10.1016/j.smim.2023.101730. Epub 2023 Feb 22. Semin Immunol. 2023. PMID: 36827760 Free PMC article. Review. - InvitroSPI and a large database of proteasome-generated spliced and non-spliced peptides.
Roetschke HP, Rodriguez-Hernandez G, Cormican JA, Yang X, Lynham S, Mishto M, Liepe J. Roetschke HP, et al. Sci Data. 2023 Jan 10;10(1):18. doi: 10.1038/s41597-022-01890-6. Sci Data. 2023. PMID: 36627305 Free PMC article. - An unexplored angle: T cell antigen discoveries reveal a marginal contribution of proteasome splicing to the immunogenic MHC class I antigen pool.
Verkerk T, Koomen SJI, Fuchs KJ, Griffioen M, Spaapen RM. Verkerk T, et al. Proc Natl Acad Sci U S A. 2022 Jul 19;119(29):e2119736119. doi: 10.1073/pnas.2119736119. Epub 2022 Jul 8. Proc Natl Acad Sci U S A. 2022. PMID: 35858315 Free PMC article. - Neo-Splicetopes in Tumor Therapy: A Lost Case?
Kloetzel PM. Kloetzel PM. Front Immunol. 2022 Feb 21;13:849863. doi: 10.3389/fimmu.2022.849863. eCollection 2022. Front Immunol. 2022. PMID: 35265089 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources